P2Y12 inhibitor or aspirin after percutaneous coronary intervention Post date 4 June 2025 ← Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis → Dapagliflozin and metabolic dysfunction-associated steatohepatitis